carecentrix

Provider Newsflash May 6, 2019

FDA RECALL

Purpose of this communication:

We are writing to inform you that effective immediately the FDA has issued a voluntary recall of one lot of Mycophenolate Mofetil for Injection, USP, lot AD812 manufactured by Gland Pharma Limited and distributed nationwide by Par Pharmaceutical, Inc. between January 23, 2019 and February 11, 2019 due to the presence of a glass fragment found in one vial of the product after reconstitution.

What do I need to do?

- Please review the following recall notice:
- https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-pharmaceutical-inc-issues-voluntary-nationwide-recall-one-lot-mycophenolate-mofetil-injection?utm_campaign=Par%20Pharmaceutical%2C%20Inc.%20Issues%20Voluntary%20Nationwide%20Recall%20of%20One%20Lot%20of%20Mycophenolate%20Mofetil&utm_medium=email&utm_source=Eloqua
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by:
    - Faxing information– To: 919-792-6718 Attn: Quality Department

Thank you for your prompt attention and cooperation in this matter.